The US Food and Drug Administration (FDA) has released guidance designed to help industry and investigators navigate the COVID-19 pandemic and help assess how to move forward with critical clinical trials.
The FDA wants to support the continuance of clinical trials in compliance with good clinical practice and minimising risks to trial integrity, while also safeguarding the health and well-being of study participants.